Browse the corpus

Colchicine is FDA-approved for gout prevention, treatment of acute gouty flares, and familial Mediterranean fever. Off-label applications include hepatic cirrhosis, primary biliary cirrhosis, and pseudogout. The primary mechanism of action involves anti-inflammatory effects, which are central to managing these conditions. Understanding the pharmacodynamics, dosing, adverse event profile, and toxicity is essential for optimizing patient outcomes. This educational activity reviews the clinical application of colchicine, emphasizing strategies to balance efficacy with safety. The program examines monitoring protocols and precautions to reduce adverse effects. The interprofessional healthcare team's role in administering and managing colchicine therapy is highlighted, emphasizing collaborative care approaches. Evidence-based strategies are discussed to enhance the effectiveness of colchicine while minimizing risks, ultimately improving care for patients with gout and related conditions. Objectives: Evaluate various hypothesized mechanisms of action of colchicine. Identify the primary and secondary indications for colchicine. Assess the contraindications for colchicine therapy. Determine the importance of interprofessional communication in improving care coordination among interprofessional team members when initiating colchicine therapy. Access free multiple choice questions on this topic.

The precise dose of colchicine that results in significant toxicity is unknown. Toxicity can occur after ingesting a dose as low as 7 mg over 4 days, while other patients have survived after taking doses exceeding 60 mg. In one review involving 150 patients who experienced a colchicine overdose, ingesting doses exceeding 0.8 mg/kg resulted in death. Acute colchicine toxicity usually begins within 24 hours of ingestion and includes gastrointestinal symptoms, eventually leading to significant fluid loss and volume depletion. In this initial phase, peripheral leukocytosis may also be present. Life-threatening complications often occur 24 to 72 hours after administration and are usually attributed to multi-organ failure. Death is typically a result of respiratory depression and cardiovascular collapse. Treatment of colchicine poisoning should start with gastric lavage and measures to prevent shock. Otherwise, treatment is symptomatic and supportive. There is no known specific antidote, and colchicine is not effectively removed by dialysis.

Before prescribing or administering colchicine to patients, providers must know the current dosing recommendations and any restrictions based on the patient's age and renal and liver function. At least 30% of all colchicine-related medication errors are related to incorrect dosing regimens. Also, it is important to know what else the patient is taking to prevent lethal drug interactions. Clinicians should ensure the patient knows how to take colchicine and that it is not an analgesic agent. Many errors have occurred with colchicine simply because patients did not know that the intended effects can take 24 to 36 hours to develop, and the patient should avoid taking repeated doses within this period. Further, patients should understand that they should discontinue colchicine if they develop gastrointestinal side effects or paresthesias. Finally, all patients must be educated on how to safely store colchicine in the home, away from the reach of children. Colchicine has a very high mortality rate should a high dose be ingested within a short time.[18][1] Prescribers should work closely with the pharmacist and the nursing staff when initiating colchicine therapy. All providers need to provide patient counseling to emphasize the crucial points. The prescriber and pharmacist should review all patient parameters and ensure dose adjustments are unnecessary. Nurses should be familiar with signs of toxicity or adverse events to monitor the patient and inform the prescriber of any issues.